TENX · Tenax Therapeutics, Inc.

The thesis

Tenax Therapeutics' recovery case depends on the US Food and Drug Administration (FDA) accepting a narrower, enriched LEVEL-2 trial of TNX-103 (oral levosimendan) after the first LEVEL trial missed its main goal. The FDA's response to the Type C meeting that Tenax requested on 8 October 2026 settles whether the case survives. A Type C meeting is a formal FDA discussion on a development question.

No FDA outcome has been disclosed since the 8 October 2026 Form 8-K. The shares closed at $1.76 on 22 October 2026, down from $1.87 on 9 October 2026 and 90.4% below the $18.32 52-week high, according to adjusted daily closes. The three-month price change is -89.1%.

The trial facts are unchanged. Tenax's 10 August 2026 topline release showed a 3.5-metre placebo-adjusted difference in six-minute walk distance, with p=0.63. The 29 August 2026 presentation at the ESC Congress reported a 26.3-metre difference, with nominal p=0.0112, in the 119 patients whose baseline walk was below the trial median. That is a hypothesis drawn after a failed primary result.

The narrative is maturing: the story is well known, and the only company disclosure since the 29 August 2026 presentation is the 8 October 2026 8-K. The newest item in company news, dated 22 October 2026, is a report of a beneficial ownership change by ADAR1 Capital Management; its direction and size are not stated in the headline.

Bullish and bearish views on Tenax Therapeutics, Inc.

The bull case on Tenax Therapeutics, Inc. (TENX), in brief: The company is acting on the subgroup. The bear case: The full trial failed.

Bull case

• The company is acting on the subgroup. The 8-K dated 8 October 2026 says Tenax will amend LEVEL-2 enrollment criteria to favour the patients LEVEL results suggest respond best. Enrollment resumes site by site as the amended protocol takes effect.
• A regulatory step is requested. The same 8-K says Tenax asked the FDA for a Type C meeting on the overall development of levosimendan. Agreement on the enriched population, if the company discloses it, would support the LEVEL-2 design.
• Cash was ample at mid-year. Tenax's 31 July 2026 results reported $118.0 million in cash and cash equivalents at 30 June 2026 and a second-quarter net loss of $17.8 million. The figure predates the LEVEL failure.
• Insiders and a large holder have been buyers. Director Declan Doogan reported buying 53,000 shares at $1.92 on 16 September 2026 in an SEC Form 4 filed 17 September 2026. A Schedule 13G lists ADAR1 Capital Management with 5,257,389 shares at an event date of 31 August 2026.

Bear case

• The full trial failed. The 10 August 2026 release said LEVEL missed its primary walk-distance endpoint. The 26.3-metre subgroup result carries a nominal p-value and does not offset the overall result.
• The enrichment details are thin. The 8-K body does not state the new criteria, the number of patients already enrolled or a resumption date. It points to an investor presentation for specifics.
• The pause delays the trial. Enrollment stops until each site adopts the amended protocol, and the FDA meeting has no disclosed date. A narrower population also slows enrollment and limits how widely a positive result applies.
• Analyst targets predate the failure. Canaccord Genuity initiated with a Buy rating and a $35 target on 28 July 2026, and Evercore ISI initiated with an Outperform rating and a $39 target on 22 July 2026. Both came before the 10 August 2026 result, and company news shows no later revisions.
• The shares have drifted lower. The 22 October 2026 close of $1.76 is below the 16 September 2026 director purchase price of $1.92 and below the $1.87 close of 9 October 2026.

Price setup

The adjusted close was $1.76 on 22 October 2026, with a 14-day Relative Strength Index (RSI) of 39.4. That reading sits below the midpoint and above the oversold line of 30. The close stands $0.06 above the $1.70 weekly-close threshold published on 30 August 2026, so a small further decline would test it.

Crowding evidence is limited. The next earnings report, estimated around 15 November 2026, is about three weeks away. SEC Form 4 filings show a director purchase on 16 September 2026 and no insider sale. Company news shows no heavy retail attention item beyond routine health-care mover lists. Ownership has concentrated: ADAR1 Capital Management's Schedule 13G lists 5,257,389 shares.

The shares sit 90.4% below the 52-week high of $18.32, so no gap above a rising moving average exists. Price is governed by the FDA response and the cash picture, not by trend.

Catalysts, next 30 days

• ~15 November 2026, est. Third-quarter 2026 results and Form 10-Q. The filing would show post-LEVEL spending and cash against the $118.0 million at 30 June 2026, and may update the LEVEL-2 timeline.
• ~22 December 2026, est. Outer date for the Type C meeting. This follows the FDA's 75-day user-fee goal for such meetings; Tenax has not announced a date. It falls outside the 30-day window but the case turns on it.

Elapsed catalysts

• Undated — FDA Type C meeting. Tenax requested it on 8 October 2026 and has announced no date. The FDA's view on an enriched LEVEL-2 population decides the regulatory case. (passed 29d ago)

What would change the view

The regulatory case breaks if Tenax discloses that the FDA did not accept an enriched LEVEL-2 population, or asked for a different confirmatory programme. A third-quarter filing that shows a short cash runway, or a financing needed before the second quarter of 2028, would also weaken it. A weekly close below $1.70 would end the thesis on price.

A disclosed FDA agreement on the enrichment, with a dated enrollment restart, would strengthen the case. A rating above LOW would need that disclosure or equivalent evidence that the subgroup result holds.

What it trades with

TENX trades on company-specific regulatory and clinical events, not on a sector theme. Its path over the next month depends on the FDA response and the third-quarter filing. Small-cap clinical-stage biotech peers react to funding conditions and sector sentiment, but no peer-correlation figure is available for this note.